ArticleProbiotics and antimicrobial proteins2026
Immunomodulatory and Gut Microbiota-Regulating Effects of Lactobacillus helveticus LH76 in Healthy Adults: Preclinical Safety Assessment and a Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational Design of a Trivalent Multi-Epitope mRNA Vaccine Candidate Against Western, Eastern, and Venezuelan Equine Encephalitis Viruses.Pharmaceutical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactobacillus helveticus LH76 is a candidate strain with potential probiotic properties, but its safety and functional effects have not been comprehensively characterized. In this study, we systematically evaluated the safety profile and potential immunomodulatory and gut microbiota-modulating effects of LH76 through integrated genomic, preclinical, and clinical approaches. Preclinical safety assessment included whole-genome sequencing and bioinformatics analyses (AMRFinder, CARD, ResFinder, VFDB, and PathogenFinder), in vitro assays of hemolysis, biogenic amine production, and cytotoxicity in Caco-2 cells, as well as a 14-day acute oral toxicity study in mice. An 8-week randomized, double-blind, placebo-controlled trial was subsequently conducted in healthy adults to assess safety, immune-related biomarkers (IgA, IgM, IgG, C3, C4, LL-37, and calprotectin), and gut microbiota composition by 16 S rRNA sequencing. LH76 showed no detectable antibiotic resistance or classical virulence genes, no hemolytic activity, negligible biogenic amine production, and no detectable cytotoxicity in vitro, while no adverse effects or pathological abnormalities were observed in vivo. In the clinical trial, LH76 was well tolerated and was not associated with adverse changes in hematological, biochemical, or metabolic parameters. Compared with placebo, LH76 supplementation was associated with increased serum IgM and C3 levels, decreased C4 and LL-37 levels, increased microbial richness, and relative enrichment of genera including Blautia and Bifidobacterium. PICRUSt2-based analysis further suggested shifts in predicted microbial metabolic pathways, although these findings remain inferential. Overall, LH76 demonstrated a favorable safety profile, was well tolerated in healthy adults at the administered daily dose of 3 × 10¹⁰ CFU/day for 8 weeks and showed an acute oral LD
Indexed as
Identifiers
42329317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.